Venetoclax is a specific BCL‐2 inhibitor that has been approved to treat relapsed chronic lymphocytic leukaemia (CLL)2 and shown clinical efficacy in MCL patients, especially when combined with ibrutinib.3, 4, 5. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.